%0 Journal Article
%T Allocation and value of curative oncological treatment in frail and fit older patients with esophageal cancer: An observational cohort study.
%A van der Poort EKJ
%A van Holstein Y
%A Slingerland M
%A Trompet S
%A van den Bos F
%A Portielje JEA
%A Steyerberg EW
%A van den Akker-van Marle ME
%A Bos WJW
%A Mooijaart SP
%A van den Hout WB
%J J Geriatr Oncol
%V 15
%N 7
%D 2024 Sep 12
%M 39138114
%F 3.929
%R 10.1016/j.jgo.2024.102046
%X <B>BACKGROUND: </B>The Value-Based Health Care (VBHC) model of care provides insights into patient characteristics, outcomes, and costs of care delivery that help clinicians counsel patients. This study compares the allocation and value of curative oncological treatment in frail and fit older patients with esophageal cancer in a dedicated VBHC pathway.<BR><B>METHODS: </B>Data was collected from patients with primary esophageal cancer without distant metastases, aged 70 years or older, and treated at a Dutch tertiary care hospital between 2015 and 2019. Geriatric assessment (GA) was performed. Outcomes included treatment discontinuation, mortality, quality of life (QoL), and physical functioning over a one-year period. Direct hospital costs were estimated using activity-based costing.<BR><B>RESULTS: </B>In this study, 89 patients were included with mean age 75 years. Of 56 patients completing GA, 19 were classified as frail and 37 as fit. For frail patients, the treatment plan was chemoradiotherapy and surgery (CRT&S) in 68% (13/19) and definitive chemoradiotherapy (dCRT) in 32% (6/19); for fit patients, CRT&S in 84% (31/37) and dCRT in 16% (6/37). Frail patients discontinued chemotherapy more often than fit patients (26% (5/19) vs 11% (4/37), p = 0.03) and reported lower QoL after six months (mean 0.58 [standard deviation (SD) 0.35] vs 0.88 [0.25], p < 0.05). After one year, 11% of frail and 30% of fit patients reported no decline in physical functioning and QoL and survived. Frail and fit patients had comparable mean direct hospital costs (€24 K [SD €13 K] vs €23 K [SD €8 K], p = 0.82).<BR><B>CONCLUSIONS: </B>The value of curative oncological treatment was lower for frail than for fit patients because of slightly worse outcomes and comparable costs. The utility of the VBHC model of care depends on the availability of sufficient data. Real-world evidence in VBHC can be used to inform treatment decisions and optimization in future patients by sharing results and monitoring performance over time.<BR><B>BACKGROUND: </B>The study was retrospectively registered at the Netherlands Trial Register (NTR), trial number NL8107 (date of registration: 22-10-2019).